Most searched codes in this range
Monthly US Google searches for the bare code (Google Ads, October 2026) show which entries coders and billers look up most; demand is one input to the index decision for each page and to which pages the hubs link first.
| Code | Description | Payment limit | Searches / month |
|---|---|---|---|
| Q9967 | Locm 300-399mg/ml iodine,1ml | $0.186 | 1,000 |
| Q5136 | Inj. denosumab-bbdz, 1 mg | $26.991 | 880 |
| Q0138 | Ferumoxytol, non-esrd | $0.331 | 720 |
| Q5103 | Injection, inflectra | $28.456 | 720 |
| Q5111 | Injection, udenyca 0.5 mg | $128.967 | 720 |
| Q5115 | Inj truxima 10 mg | $35.988 | 720 |
| Q5106 | Inj retacrit non-esrd use | $8.171 | 590 |
| Q5108 | Injection, fulphila | $55.964 | 590 |
| Q5107 | Inj mvasi 10 mg | $28.294 | 480 |
| Q5119 | Inj ruxience, 10 mg | $5.792 | 590 |
Codes in this range
85 of the 95 codes carry a published October 2026 ASP payment limit, 10 show their OPPS rate instead; the remaining codes are priced by contractors or carry a limit of zero in the file. The table lists the 81 codes whose reference pages are indexed; the other 14 follow as a list.
| Code | Descriptor | Unit | Limit | MUE | Col-2 pairs | Articles |
|---|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 1 MG | $0.331 | 510 | — | — |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 1 MG | $0.016 | 0 | — | — |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | 1 MG | $0.774 | 0 | — | — |
| Q0167 | Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 2.5 MG | $2.092 | 0 | — | — |
| Q0224 | Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg | 4500 MG | $7,615.20 | 1 | — | — |
| Q0237 | Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | 1 MG | $4.92 | — | — | — |
| Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | 1 MG | $7.569 | 1600 | — | — |
| Q2009 | Injection, fosphenytoin, 50 mg phenytoin equivalent | 50 MG PE/ML | $1.552 OPPS | 100 | — | — |
| Q2026 | Injection, radiesse, 0.1 ml | 0.1 ml | $349.19 OPPS | 30 | — | yes |
| Q2028 | Injection, sculptra, 0.5 mg | 0.5 mg | $2.16 OPPS | 1470 | — | yes |
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Per infusion (minimum 50 million cells) | $55,663.131 | 1 | 1 | yes |
| Q2049 | Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg | 10 mg | $298.74 OPPS | 10 | — | — |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg | 10 MG | $97.823 | 14 | — | — |
| Q2057 | Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose | PER THERAPEUTIC DOSE | $813,967.375 | 1 | — | — |
| Q2058 | Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion | Per Therapeutic Dose | $293,725.702 | 1 | — | — |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 100 UNITS | $0.667 | 100 | — | yes |
| Q5098 | Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg | 1 MG | $9.27 | 520 | — | — |
| Q5099 | Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg | 1 MG | $2.89 | 520 | — | — |
| Q5100 | Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg | 1 MG | $3.08 | 520 | — | — |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 1 MCG | $0.338 | 1500 | — | yes |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 10 MG | $28.456 | 150 | — | yes |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | 100 UNITS | $0.817 | 100 | — | yes |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1000 UNITS | $8.171 | 60 | — | yes |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 10 MG | $28.294 | 230 | — | yes |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 0.5 MG | $55.964 | 12 | — | yes |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 1 MCG | $0.329 | 1500 | — | yes |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 0.5 MG | $128.967 | 12 | — | yes |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | 10 MG | $32.791 | 120 | — | — |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | 10 MG | $55.295 | 120 | — | — |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 10 MG | $29.507 | 120 | — | — |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 10 MG | $35.988 | 150 | — | yes |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | 10 MG | $11.271 | 120 | — | — |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 10 MG | $63.871 | 120 | — | — |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 10 MG | $25.939 | 230 | — | yes |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 0.5 MG | $302.247 | 12 | — | yes |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 10 MG | $34.686 | 150 | — | yes |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 0.5 MG | $141.289 | 12 | — | yes |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 10 MG | $21.083 | 150 | — | yes |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 0.1 MG | $249.493 | 10 | — | yes |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 1 MCG | $0.308 | 1800 | — | yes |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 10 MG | $79.982 | 230 | — | yes |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 0.5 MG | $163.948 | 12 | — | yes |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 0.1 MG | $81.13 | 10 | — | yes |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 10 MG | $21.139 | 230 | — | yes |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | 0.5 MG | $94.292 | 12 | — | yes |
| Q5133 | Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg | 1 MG | $4.706 | 1200 | — | — |
| Q5134 | Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg | 1 MG | $24.397 | 300 | — | — |
| Q5135 | Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg | 1 MG | $4.37 | 1200 | — | — |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | 1 MG | $26.991 | 120 | — | yes |
| Q5138 | Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg | 1 MG | $2.273 | 520 | — | — |
| Q5146 | Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg | 10 MG | $30.255 | 120 | — | — |
| Q5147 | Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg | 1 MG | $763.376 | 4 | — | yes |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | 1 MCG | $1.026 | 1500 | — | yes |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg | 2 MG | $31.547 | 600 | — | yes |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg | 2 MG | $40.412 | 600 | — | yes |
| Q5154 | Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg | 5 mg | $46.61 OPPS | — | — | yes |
| Q5156 | Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg | 1 MG | $3.098 | — | — | — |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | 1 MG | $24.002 | — | — | yes |
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | 1 MG | $28.702 | — | — | yes |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | 10 MG | $82.139 | 230 | — | yes |
| Q5161 | Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg | 1 MG | $27.509 | — | — | — |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | 1 MG | $15.336 | — | — | yes |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | 1 mg | $29.72 OPPS | — | — | yes |
| Q5167 | Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg | 1 MG | $7.681 | — | — | yes |
| Q5168 | Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg | 0.1 MG | $26.384 | — | — | yes |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | 0.5 MG | $519.481 | — | — | yes |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 1 ML | $18.052 | 5 | — | yes |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 1 ML | $40.323 | 9 | — | yes |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 1 ML | $0.08 | 300 | 4 | — |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 1 ML | $0.205 | 200 | 2 | — |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 1 ML | $0.219 | 240 | — | — |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 1 ML | $1.787 | 250 | 7 | — |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 1 ML | $0.421 | 250 | 6 | — |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1 ML | $0.186 | 300 | 5 | — |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 1 MG | $8.541 OPPS | 200 | — | — |
| Q9982 | Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries | up to 5 millicuries | $1,944.01 OPPS | 1 | — | — |
| Q9983 | Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries | PER STUDY DOSE, UPTO 8 mCi | $1,584.67 OPPS | 1 | — | — |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | Less than or equal to 100 MG | $2,060.132 | 1 | — | — |
| Q9997 | Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg | 1 MG | $8.591 | 520 | — | — |
| Q9998 | Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg | 1 MG | $10.48 | 520 | — | — |
| Q9999 | Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg | 1 MG | $13.246 | 520 | — | — |
Show the other 14 codes on this page (pages not yet in search results)
- Q0139 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) · limit $0.331
- Q0234 Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg · limit $6.327
- Q0238 Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg · limit $5.581
- Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $577,943.258
- Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $626,315.834
- Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $532,352.741
- Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $589,846.771
- Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $575,850.465
- Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $594,112.255
- Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg · limit $25.649
- Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg · limit $5.792
- Q5172 Injection, filgrastim-laha (filkri), biosimilar, 1 microgram · OPPS $0.74
- Q9957 Injection, perflutren lipid microspheres, per ml · limit $40.323
- Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg · limit $2,060.132
How to read this table
The limit is the Medicare Part B payment allowance per billing unit for the quarter shown, not per dose: multiply it by the units that the administered quantity divided by the descriptor unit produces. Codes marked OPPS have no ASP limit and show the hospital outpatient rate per unit instead. The MUE column is the practitioner-setting Medically Unlikely Edit, the maximum units CMS expects on one date of service; facility and DME limits can differ and appear on each code page. Column-2 pairs counts the active NCCI procedure-to-procedure edits in which the code is the bundled component, and Articles marks codes that at least one Medicare Administrative Contractor lists in a current Billing and Coding Article with covered diagnosis codes. Codes without a published limit are contractor-priced or carry a zero limit in the CMS file.
In QuickIntell research
- October 2026 ASP movers report: The 75 drug codes whose payment limit moved 20% or more since July 2026, and the 37 priced for the first time.
- October 2026 HCPCS update report: The codes CMS added and discontinued in the latest quarterly release, with replacements; the 2026 roll-up covers every quarter.
- 2026 Q4 most-bundled codes report: The codes NCCI bundles most often as column 2, and the 12 Part B drug codes it bundles at all.
- J codes by drug name: Find the J code, or every code, for a drug by generic or brand name.
For teams evaluating QuickIntell software
Evaluate software for HCPCS coding workflows
Evaluating a recurring coding workflow? Review QuickCode for qualified coder review, documentation clarification and the billing handoff. Use your unit, modifier and edit questions to confirm the supported scope; a published CMS table does not establish an automated claim check.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
How many codes are in temporary codes (q codes)?
95 Part B drug codes in this range: 85 carry an ASP payment limit in the October 2026 file and 10 are paid separately under OPPS without an ASP limit; 81 have enough joined CMS data (MUE, NCCI, OPPS, ASC or coverage) to be published as full reference pages.
Which payers use these payment limits?
Medicare Part B contractors apply the ASP limits directly. Medicaid programs and commercial payers publish their own fee schedules, which often reference ASP but at different percentages.
Why do some codes show no MUE?
CMS withholds some MUE values as confidential and applies them without publication; others have no unit limit. A code with no published MUE can still deny for units when the quantity is implausible for the dose.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
Disclaimer
Operational reference compiled from CMS publications. Payment limits are Medicare national amounts; other payers differ. CPT codes appear as numbers only. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.